Skip to main content
QMSQMS
QMS
  • Welcome to your QMS
  • Quality Manual
  • Procedures
  • Records
  • Legit.Health Plus Version 1.1.0.0
    • Index
    • Overview and Device Description
    • Information provided by the Manufacturer
    • Design and Manufacturing Information
      • R-TF-012-019 SOUPs
      • R-TF-012-028 Software Requirement Specification
      • R-TF-012-029 Software Architecture Description
      • R-TF-012-030 Software Configuration Management Plan
      • R-TF-012-031 Product requirements specification
      • R-TF-012-037 Labeling and IFU Requirements
      • R-TF-012-040 Documentation level FDA
      • R-TF-012-041 Software Classification 62304
      • R-TF-012-043 Traceability Matrix
      • Review meetings
        • Phase 1: Product Design Review
        • Phase 2: Software Design Review
        • Phase 3: Software Development Review (Release Candidate)
        • Phase 4: Software Verification Review
        • Phase 5: Product Validation Review
    • GSPR
    • Benefit-Risk Analysis and Risk Management
    • Product Verification and Validation
    • Post-Market Surveillance
  • Legit.Health Plus Version 1.1.0.1
  • Licenses and accreditations
  • Applicable Standards and Regulations
  • Pricing
  • Public tenders
  • Legit.Health Plus Version 1.1.0.0
  • Design and Manufacturing Information
  • Review meetings
  • Phase 1: Product Design Review

Phase 1: Product Design Review

Process Overview​

The purpose of the Product Design review (Phase 1) is to ensure that the outputs of Product Design satisfy the criteria required to move forward to Phase 2 (Software Design). This review validates that the product concept, intended use, and high-level requirements are clearly defined and ready for technical implementation.

According to GP-012, Phase 1 establishes the foundation for all subsequent development phases.

General Information​

Information
Device nameLegit.Health Plus (hereinafter, the device)
Model and typeNA
Version1.1.0.0
Basic UDI-DI8437025550LegitCADx6X
Certificate number (if available)MDR 792790
EMDN code(s)Z12040192 (General medicine diagnosis and monitoring instruments - Medical device software)
GMDN code65975
EU MDR 2017/745Class IIb
EU MDR Classification ruleRule 11
Novel product (True/False)TRUE
Novel related clinical procedure (True/False)TRUE
SRNES-MF-000025345

Project Information​

  • Project title: Legit.Health Plus Version 1.1.0.0
  • Project manager: JD-003 (Design & Development Manager)
  • Review date: [Date to be completed]
  • Reviewers: JD-001 (General Manager), JD-003 (Design & Development Manager), JD-007 (Technical Manager), JD-004 (Quality Manager & PRRC)

Context of Initialization​

This project was initiated to develop Legit.Health Plus Version 1.1.0.0, a medical device software designed for dermatological diagnosis and disease tracking. The device addresses the medical need for objective, consistent, and scalable assessment of skin conditions using AI/ML-powered image analysis.

Key technological elements include:

  • Machine learning models for skin condition recognition
  • Image processing and analysis
  • User interface for clinicians
  • Integration with healthcare systems

This is an evolution of previous versions, incorporating regulatory compliance improvements and enhanced functionality for EU MDR and FDA requirements.

Planning​

PhaseObjectDone
Phase 1 Product Design ReviewEstablish input data✓
Phase 2 Software Design ReviewSRs, Architectural Design and UI Prototypes
Phase 3 Software DevelopmentCoding, integration and test plan
Phase 4 Software Verification ReviewSoftware version verified and residual anomalies
Phase 5 Product Validation ReviewValidation activities, Technical Documentation and DHF

Product Design Checklist​

Device Description and Intended Use​

ItemStatusReference
Description of the Intended Use✓Description and Specifications
Device Description (operating principles, core functions)✓Description and Specifications
STED (Summary of Technical Documentation)✓STED

Product Requirements​

ItemStatusReferenceComments
List of product requirements documented✓Software Development PlanProduct Requirements (PRs) are defined and documented
Requirements are complete✓All stakeholder needs addressed
Requirements are understandable✓Clear language, no ambiguity
Requirements are consistent✓No contradictions between requirements
Requirements are feasible✓Technically and commercially viable
Requirements do not contradict one another✓Internal consistency verified
Requirements are uniquely identified✓Each requirement has unique identifier
Requirements are traceable to intended use✓Traceability maintained throughout

Medical Device Classification​

ItemStatusValueReference
Device meets definition of medical device✓YesDescription and Specifications
Estimated medical device class (EU MDR)✓Class IIaDescription and Specifications
Estimated medical device class (FDA)✓Class IIDescription and Specifications
Estimated software class (IEC 62304)✓Class BSoftware Development Plan
Estimated software class (FDA)✓Level of Concern: ModerateSoftware Development Plan

Stakeholder Engagement​

StakeholderEngagement StatusContribution
JD-001 (General Manager)✓Business strategy and market requirements
JD-003 (Design & Development Mgr)✓Regulatory requirements and product requirements definition
JD-007 (Technical Manager)✓Technical feasibility and high-level architecture
JD-004 (Quality Manager & PRRC)✓Quality requirements and compliance verification
JD-018 (Clinical Affairs)✓Clinical needs and intended use validation

Documentation Completeness​

DocumentStatusLocation
Device Description and Specifications✓Link
STED✓Link
Product Requirements (within SDP)✓Link

Reserves and Pending Actions​

N°Issue / Action RequiredOwnerTargeted DateStatus
-No reserves identified at this phase---

Conclusion​

Review Outcome: The Phase 1 Product Design review has been successfully completed.

Assessment:

  • All design inputs and outputs are complete, available, and relevant
  • The device description and intended use are clearly documented
  • Product requirements are comprehensive, traceable, and feasible
  • Medical device and software classifications have been determined
  • All stakeholders have been engaged and provided input

Decision: The project is approved to proceed to Phase 2: Software Design.

Next Steps:

  • Initiate Software Design activities as defined in GP-012
  • Begin development of Software Requirements Specification (SRS)
  • Establish software architecture and design documents
  • Initiate parallel procedures: Risk Management, Clinical Evaluation, Cybersecurity, AI/ML Development, and Usability

Approved by:

Signature meaning

The signatures for the approval process of this document can be found in the verified commits at the repository for the QMS. As a reference, the team members who are expected to participate in this document and their roles in the approval process, as defined in Annex I Responsibility Matrix of the GP-001, are:

  • Author: Team members involved
  • Reviewer: JD-003, JD-004
  • Approver: JD-001
Previous
Review meetings
Next
Phase 2: Software Design Review
  • Process Overview
  • General Information
  • Project Information
  • Context of Initialization
  • Planning
  • Product Design Checklist
    • Device Description and Intended Use
    • Product Requirements
    • Medical Device Classification
    • Stakeholder Engagement
  • Documentation Completeness
  • Reserves and Pending Actions
  • Conclusion
All the information contained in this QMS is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI Labs Group S.L.)